Dana Pizzuti's Insider Trades & SAST Disclosures
Dana Pizzuti's most recent trade in Crinetics Pharmaceuticals Inc was a trade of 2,388 Common Stock done at an average price of $34.2 . Disclosure was reported to the exchange on March 19, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Dana Pizzuti.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 34.17 per share. | 19 Mar 2025 | 2,388 | 72,360 (0%) | 0% | 34.2 | 81,598 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 34.83 per share. | 19 Mar 2025 | 127 | 72,233 (0%) | 0% | 34.8 | 4,423 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 43,000 | 74,748 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 03 Feb 2025 | 5,000 | 36,748 (0%) | 0% | 16.9 | 84,450 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 39.07 per share. | 03 Feb 2025 | 5,000 | 31,748 (0%) | 0% | 39.1 | 195,350 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 5,000 | 119,042 | - | - | Stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 03 Jan 2025 | 15,000 | 44,248 (0%) | 0% | 16.9 | 253,350 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 52.09 per share. | 03 Jan 2025 | 15,000 | 29,248 (0%) | 0% | 52.1 | 781,350 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 15,000 | 124,042 | - | - | Stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.64 per share. | 03 Jan 2025 | 2,500 | 31,748 (0%) | 0% | 19.6 | 49,100 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 2,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 03 Oct 2024 | 14,375 | 42,882 (0%) | 0% | 16.9 | 242,794 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2024 | 14,375 | 139,042 | - | - | Stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 54.63 per share. | 03 Oct 2024 | 14,375 | 28,507 (0%) | 0% | 54.6 | 785,306 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jul 2024 | 14,375 | 153,417 | - | - | Stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 44.87 per share. | 03 Jul 2024 | 14,375 | 28,507 (0%) | 0% | 44.9 | 645,006 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 03 Jul 2024 | 14,375 | 42,882 (0%) | 0% | 16.9 | 242,794 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 24 Jun 2024 | 9,500 | 37,286 (0%) | 0% | 16.9 | 160,455 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 9,500 | 167,792 | - | - | Stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 45.73 per share. | 24 Jun 2024 | 9,500 | 27,786 (0%) | 0% | 45.7 | 434,435 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 14,375 | 177,292 | - | - | Stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 44.47 per share. | 15 Apr 2024 | 14,375 | 27,786 (0%) | 0% | 44.5 | 639,256 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 15 Apr 2024 | 14,375 | 42,161 (0%) | 0% | 16.9 | 242,794 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 10,000 | 191,667 | - | - | Stock Option (right to buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 43.28 per share. | 20 Mar 2024 | 10,000 | 28,500 (0%) | 0% | 43.3 | 432,800 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 20 Mar 2024 | 10,000 | 38,500 (0%) | 0% | 16.9 | 168,900 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 4,375 | 201,667 | - | - | Stock Option (right to buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 45.89 per share. | 20 Mar 2024 | 4,375 | 28,500 (0%) | 0% | 45.9 | 200,769 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 20 Mar 2024 | 4,375 | 32,875 (0%) | 0% | 16.9 | 73,894 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 43.69 per share. | 20 Mar 2024 | 714 | 27,786 (0%) | 0% | 43.7 | 31,195 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.14 per share. | 18 Mar 2024 | 411 | 28,500 (0%) | 0% | 38.1 | 15,676 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 87,000 | 87,000 | - | - | Stock Option (right to buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 23,000 | 28,911 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 03 Jan 2024 | 14,375 | 20,286 (0%) | 0% | 16.9 | 242,794 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 03 Jan 2024 | 14,375 | 5,911 (0%) | 0% | 35 | 503,125 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2024 | 14,375 | 206,042 | - | - | Non-qualified stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2023 | 9,583 | 220,417 | - | - | Non-qualified stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.89 per share. | 21 Dec 2023 | 9,583 | 15,494 (0%) | 0% | 16.9 | 161,857 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Med and Dev Officer | Sale of securities on an exchange or to another person at price $ 34.57 per share. | 21 Dec 2023 | 9,583 | 5,911 (0%) | 0% | 34.6 | 331,284 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 16.15 per share. | 03 Apr 2023 | 8,212 | 4,500 (0%) | 0% | 16.2 | 132,624 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.98 per share. | 03 Apr 2023 | 4,288 | 12,712 (0%) | 0% | 16.0 | 68,522 | Common Stock |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 4,500 | 17,000 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2022 | 230,000 | 230,000 | - | - | Stock Option (right to buy) | |
| Crinetics Pharmaceuticals Inc | Dana Pizzuti | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2022 | 12,500 | 12,500 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges